Caribou Biosciences, Inc. (CRBU)

NASDAQ: CRBU · IEX Real-Time Price · USD
11.01
+0.41 (3.87%)
At close: Oct 4, 2022 4:00 PM
11.11
+0.10 (0.91%)
After-hours: Oct 4, 2022 6:10 PM EDT
3.87%
Market Cap 666.70M
Revenue (ttm) 13.39M
Net Income (ttm) -85.24M
Shares Out 60.55M
EPS (ttm) -1.64
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 371,947
Open 11.05
Previous Close 10.60
Day's Range 10.80 - 11.52
52-Week Range 4.89 - 24.00
Beta n/a
Analysts Buy
Price Target 29.29 (+166.0%)
Earnings Date Sep 1, 2022

About CRBU

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The compa... [Read more...]

Industry Biotechnology
IPO Date Jul 23, 2021
Employees 2,021
Stock Exchange NASDAQ
Ticker Symbol CRBU
Full Company Profile

Financial Performance

In 2021, CRBU's revenue was $9.60 million, a decrease of -22.35% compared to the previous year's $12.36 million. Losses were -$66.92 million, 95.1% more than in 2020.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for CRBU stock is "Buy." The 12-month stock price forecast is 29.29, which is an increase of 166.03% from the latest price.

Price Target
$29.29
(166.03% upside)
Analyst Consensus: Buy
Stock Forecasts

News

This Biotech Stock Could Offer Big Growth – Even During A Recession

Caribou Biosciences is the biotech behind some cutting-edge cancer therapies

1 month ago - The Motley Fool

Caribou Biosciences to Participate in Upcoming Investor Conferences

BERKELEY, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company's part...

1 month ago - GlobeNewsWire

Caribou Biosciences, Inc. (CRBU) Reports Q2 Loss, Tops Revenue Estimates

Caribou Biosciences, Inc. (CRBU) delivered earnings and revenue surprises of -24.32% and 48.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Caribou Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update

-- 6-month CR in 3 of 6 patients across cohort 1 of the CB-010 ANTLER Phase 1 clinical trial -- -- Additional cohort 1 data expected by YE 2022; enrolling patients in cohort 2 of ANTLER trial --

1 month ago - GlobeNewsWire

7 Cheap Biotech Stocks to Buy Now

Biopharmaceutical companies have been struggling since 2021 and that narrative isn't immediately changing. However, not every firm deserves this fate.

2 months ago - InvestorPlace

Analysts Remain Bullish Despite Caribou's Allogeneic CAR-T Hit By Durability

Caribou Biosciences Inc (NASDAQ: CRBU) announced the presentation of additional initial clinical data from its ANTLER Phase 1 trial for CB-010 in relapsed or refractory B cell non-Hodgkin lymphoma (r/r ...

3 months ago - Benzinga

What's Going On With Caribou Biosciences Shares Today?

Caribou Biosciences, Inc. (NASDAQ: CRBU) shares are trading lower after the company reported additional data from its CB-010 allogeneic CAR-T cell therapy Phase 1 ANTLER trial at the European Hematology...

3 months ago - Benzinga

Caribou Biosciences Reports Positive Additional Data from CB-010 Allogeneic CAR-T Cell Therapy Phase 1 ANTLER Trial a...

-- 100% CR rate (6 of 6 patients), with 40% CR rate (2 of 5 patients) at 6 months, achieved as best response following 1 dose at the initial dose level in patients with aggressive r/r B-NHL -- -- First ...

3 months ago - GlobeNewsWire

Caribou Biosciences Announces Webcast Conference Call to Highlight Initial CB-010 ANTLER Phase 1 Data Presentation at...

-- Poster presentation at the European Hematology Association (EHA) 2022 Congress to take place on Friday, June 10 and include additional data from dose level 1 patients -- -- Poster presentation at the...

4 months ago - GlobeNewsWire

Caribou CEO discusses his company's unicorn status, its plans going forward, and its culture

Caribou CEO Kevin Bennett sits down with Yahoo Finance Live to discuss his company's business outlook after receiving funding, car price trends, and refinancing cars.

4 months ago - Yahoo Finance

Caribou Charges Ahead on Study Results

Shares of Caribou Biosciences Inc. ( CRBU , Financial) are up more than 46% since last Thursday, leading the way for several beaten-down biotechs that also rose after investors got a look at the present...

4 months ago - GuruFocus

Caribou Biosciences Announces Appointment of David Johnson to its Board of Directors

-- Mr. Johnson brings 30 years of commercial experience to Caribou as company's pipeline of genome-edited cell therapies advances -- -- Mr. Johnson brings 30 years of commercial experience to Caribou as...

4 months ago - GlobeNewsWire

Caribou Biosciences Reports First Quarter 2022 Financial Results and Provides Business Updates

-- Initial ANTLER Phase 1 clinical data scheduled to be shared at the European Hematology Association (EHA) 2022 Hybrid Congress for CB-010, the Company's lead allogeneic cell therapy candidate, in pati...

4 months ago - GlobeNewsWire

Caribou Biosciences to Present at Upcoming Investor Conference

BERKELEY, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwit...

5 months ago - GlobeNewsWire

Caribou Biosciences Announces Presentation of chRDNA Platform Data at the 25th Annual Meeting of the American Society...

-- Data highlight the mechanism underlying the superior specificity of Caribou's chRDNA genome-editing technology in primary human T cells -- -- Data highlight the mechanism underlying the superior spec...

5 months ago - GlobeNewsWire

Caribou Biosciences to Share CB-010 Initial Clinical Data at the Upcoming European Hematology Association (EHA) 2022 ...

-- Abstract accepted on initial clinical data from the ANTLER Phase 1 trial of CB-010, Caribou's lead allogeneic cell therapy for patients with r/r B-NHL -- -- Abstract accepted on initial clinical data...

5 months ago - GlobeNewsWire

Caribou Biosciences Presents Positive Preclinical Data for Allogeneic Anti-BCMA CAR-T Cell Therapy Candidate CB-011 a...

-- CB-011 is an allogeneic anti-BCMA CAR-T cell therapy immune cloaked  to blunt both T- and NK-mediated immune cell rejection,  enabling more durable antitumor activity -- -- Data support an expected I...

5 months ago - GlobeNewsWire

Caribou Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

-- Company plans to present initial ANTLER Phase 1 clinical data at a medical meeting in 2022 for CB-010, its lead allogeneic cell therapy candidate  for patients with r/r B-NHL -- -- 2022 submission of...

6 months ago - GlobeNewsWire

Caribou Biosciences to Present Preclinical Data on CB-011, an Immune-Cloaked Allogeneic Anti-BCMA CAR-T Cell Therapy,...

BERKELEY, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that preclinical ...

6 months ago - GlobeNewsWire

Caribou Biosciences to Present at Upcoming Investor Conferences

BERKELEY, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurw...

6 months ago - GlobeNewsWire

Caribou Biosciences to Present at the SVB Leerink 11th Annual Global Healthcare Conference

BERKELEY, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwit...

7 months ago - GlobeNewsWire

Caribou Biosciences Appoints Syed Rizvi, M.D., as Chief Medical Officer

Dr. Rizvi brings significant experience in oncology cell therapy development Dr. Rizvi brings significant experience in oncology cell therapy development

8 months ago - GlobeNewsWire

Caribou Biosciences to Present at 40th Annual J.P. Morgan Healthcare Conference

BERKELEY, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwit...

9 months ago - GlobeNewsWire

Caribou Biosciences Provides Business Update and Reports Third Quarter 2021 Financial Results

On track to achieve key milestones, including plan to disclose initial clinical data in 2022 for lead product candidate CB-010

10 months ago - GlobeNewsWire

Caribou Biosciences Appoints Biotechnology Industry Veteran Ran Zheng to its Board of Directors

BERKELEY, Calif., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today it has appointed R...

1 year ago - GlobeNewsWire